DOCSLIB.ORG

Invoking the Power of Thrombospondins: Regulation of Thrombospondins Expression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Invoking the Power of Thrombospondins: Regulation of Thrombospondins Expression MATBIO-01044; No of Pages 14 Matrix Biology xxx (2014) xxx–xxx Contents lists available at ScienceDirect Matrix Biology journal homepage: www.elsevier.com/locate/matbio Invoking the power of thrombospondins: Regulation of thrombospondins expression Olga Stenina-Adognravi ⁎ Department of Molecular Cardiology, Cleveland Clinic, 9500 Euclid Ave NB50, Cleveland, OH 44195, United States article info abstract Article history: Increasing evidence suggests critical functions of thrombospondins (TSPs) in a variety of physiological and path- Received 16 December 2013 ological processes. With the growing understanding of the importance of these matricellular proteins, the need to Received in revised form 5 February 2014 understand the mechanisms of regulation of their expression and potential approaches to modulate their levels is Accepted 8 February 2014 also increasing. The regulation of TSP expression is multi-leveled, cell- and tissue-specific, and very precise. Available online xxxx However, the knowledge of mechanisms modulating the levels of TSPs is fragmented and incomplete. This Keywords: review discusses the known mechanisms of regulation of TSP levels and the gaps in our knowledge that prevent Thrombospondin us from developing strategies to modulate the expression of these physiologically important proteins. Regulation of expression © 2014 Elsevier B.V. All rights reserved. Transcription Translation miRNA 1. Introduction important physiological and pathological processes, as well as under- standing that cells do not function in isolation from their environment Thrombospondins (TSPs) are secreted extracellular proteins that be- and ECM. long to a group of matricellular proteins — proteins that are present in The human TSP protein family consists of five members (TSP-1, TSP-2, the extracellular matrix (ECM), but do not play a primary structural TSP-3, TSP-4, and TSP-5, or cartilage oligomeric matrix protein, COMP), role as other ECM proteins do. Matricellular proteins, including TSPs, which are divided into two subgroups based on their domain structure have diverse functions that integrate ECM and cells: they interact with (Adams, 2001; Adams and Lawler, 2004, 2011) (TSP-1 and TSP-2 belong a number of cell surface receptors and with a variety of ECM proteins to subgroup A, while TSP-3, TSP-4, and TSP-5 compose subgroup B). In (e.g., structural proteins such as collagens, proteases, and growth lower organisms, TSPs are represented by a single protein, as in sponge factors). The revolutionary classification of matricellular proteins pro- (Bentley and Adams, 2010), or by multiple family members, e.g., five posedbylatePaulBornstein(Sage and Bornstein, 1991; Bornstein, proteins in sea anemone (Tucker et al., 2013), that have a structure sim- 1995) has promoted a better appreciation of ECM and its role in ilar to human TSPs of subgroup B. The second subgroup A appears later in the evolutionary development, coinciding with the development of the vascular system (Bentley and Adams, 2010), and develops further as a re- flection of the development of cardiovascular and immune systems wherethisgroupplaysanimportantrole. Abbreviations: AhR, Aryl (aromatic) hydrocarbon receptor; ARE, Adenylate-uridylate- rich element; ATF-1, Activating Transcription Factor-1; CBF, CCAAT-binding factor; COMP, Important physiological functions of TSPs have been discovered in Cartilage oligomeric matrix protein; Cyp1B1, Cytochrome P450 1B1; EBOX, Enhancer box; many organs and systems [reviewed in (Henkin and Volpert, 2011; ECM, Extracellular matrix; Egr-1, Early growth response protein 1; EGRF, Early growth re- Frangogiannis, 2012; Mayer et al., 2013; Stenina-Adognravi, 2013)]. sponse factor 1; eNOS, Endothelial nitric oxide synthase; ER, Endoplasmic reticulum; H3, Regulation of angiogenesis and cancer progression (Lawler and Histone 3; HDAC, Histone Deacetylase; HGF, Hepatocyte growth factor; HuR, Human anti- Lawler, 2012), regulation of inflammation (Frolova et al., 2010; Lopez- gen R; IR, Ischemia/reperfusion; MAPK, Mitogen-activated protein kinases; MI, Myocardial infarction; MYC, Myelocytomatosis oncogene; NO, Nitric oxide; NR4A2, Nuclear receptor Dee et al., 2011; Mustonen et al., 2012; Stenina-Adognravi, 2013; subfamily 4, group A, member 2; PAH, Pulmonary arterial hypertension; PAR-1, Vanhoutte et al., 2013), modulation of immune response (Martin- Protease-activated receptor-1; SPARC, Secreted protein acidic and rich in cysteine; TGFβ, Manso et al., 2012; Miller et al., 2013), formation of myotendinous junc- Transforming growth factor beta; TRPC4, Short transient receptor potential channel 4; tions (Subramanian et al., 2007), maintenance of the myocardium TSP, Thrombospondin; UTR, Untranslated region; WT1, Wilms' tumor suppressor; YY-1, integrity and function (Schroen et al., 2004; Chatila et al., 2007; Yin Yang 1. ⁎ Tel.: +1 216 444 9057 (office); fax: +1 216 445 8204. Swinnen et al., 2009; Cingolani et al., 2011; van Almen et al., 2011a; E-mail address: [email protected]. Frolova et al., 2012; Lynch et al., 2012; Roberts et al., 2012), regulation http://dx.doi.org/10.1016/j.matbio.2014.02.001 0945-053X/© 2014 Elsevier B.V. All rights reserved. Please cite this article as: Stenina-Adognravi, O., Invoking the power of thrombospondins: Regulation of thrombospondins expression, Matrix Biol. (2014), http://dx.doi.org/10.1016/j.matbio.2014.02.001 2 O. Stenina-Adognravi / Matrix Biology xxx (2014) xxx–xxx of fibrosis (Sweetwyne and Murphy-Ullrich, 2012), and synaptogenesis (Frolova et al., 2010). Similarly, in the wall of smaller blood vessels (Risher and Eroglu, 2012) are just a few examples of their roles in TSP-3, TSP-4, and TSP-5 not only are produced by different cell types, physiology and pathology. To participate in the critical physiological but also are deposited in ECM in distinct patterns and in distinct locali- processes, TSPs have to be present in the right location at the right zation within the vessel (Frolova, in press). In tendon, both TSP-3 and time. This review summarizes the published information about the TSP-4 are abundant, but are arranged in fibers of different orientations, regulation of the expression of TSPs. stressing the distinctions in their functions (Frolova, in press). When TSPs are expressed in the same structures at the same time [e.g., TSP-4 2. Similarities and distinctions between TSP family members and TSP-5 in tendon (Frolova, in press)], it is still unclear why both are required and what differential properties of tissue they support. All TSPs share a high degree of homology at the protein level, espe- Differences in the expression profiles of individual TSPs in cancers cially in their “signature domain”—the C-terminal half of the human and other cells and tissues [e.g., (Carron et al., 2000; Agah et al., 2002; protein that includes 3–4EGF-likerepeats[1–5 in other species Bornstein et al., 2004)] suggest that TSPs have differential functions in (Adams and Lawler, 2011)], the Ca2+-binding domains with up to 26 pathological processes, despite shared homologous domains and li- metal binding sites per protein subunit, and the globular C-terminal do- gands. Several gene expression studies demonstrated opposite profiles main [reviewed in (Adams and Lawler, 2011)]. Table 1 summarizes the for TSP-1 and TSP-4 in brain (Bredel et al., 2005; Liang et al., 2005; extent of homology between five TSPs. However, apart from the protein Sun et al., 2006) and breast (Sorlie et al., 2001; Turashvili et al., 2007; coding regions of the TSP genes (THBS), there is no homology in their Ma et al., 2009) cancers. Examination of the datasets from these studies DNA sequence, and the regulatory parts of TSP genes, either the reveals that TSP-4 upregulation is accompanied by downregulation of untranslated regions of mRNA (UTR) or the gene promoters, are dis- TSP-1 in the tumor samples (www.oncomine.org), clearly indicating tinctly different at the first glance (Adolph et al., 1997). Search for com- distinct, probably even opposite, functions for these two proteins. Unex- mon DNA sequence motifs using SCOPE motif finder (http://genie. pectedly, TSP-2, belonging to subgroup A and sharing high homology dartmouth.edu/scope)(Carlson et al., 2007; Chakravarty et al., 2007) with TSP-1, exhibits a profile similar to the TSP-4 profile — it is upregu- and comparison of the positions of common DNA sequence motifs in lated in both brain and breast cancers, with the exception of one data set the promoters of five TSPs reveal some similarities between TSP pro- (Bredel et al., 2005). In some datasets TSP-2 was in top 1% of upregulat- moters and suggest that in some conditions two or more TSPs may be ed genes, together with TSP-4. These comparisons of the three TSP pro- regulated by the same stimuli simultaneously (Fig. 1). However, there files from the same datasets clearly demonstrate that the three TSPs are no experimental data to support the predicted similarity of the play important distinct roles in cancer growth, and the regulation of DNA motifs. their expression is an efficient mechanism to support these still poorly The five proteins are located on different chromosomes (human understood functions (with the exception of TSP-1, whose downregula- THBS1 on chromosome 15 and mouse Thbs1 on chromosome 2, tion is known to support angiogenesis in tumors). TSP-5 was upregulat- human THBS2 on chromosome 6 and mouse Thbs2 on chromosome ed similar to TSP-4 in multiple datasets from breast cancer studies 17, human THBS3 on chromosome 1 and mouse Thbs3 on chromosome (www.oncomine.org), while TSP-3 data were inconsistent, and both 3, human THBS4 on chromosome 5 and mouse Thbs4 on chromosome 13, down-regulation and up-regulation were observed (Ramaswamy human THBS5 on chromosome 19 and mouse Thbs5 on chromosome 8). et al., 2003; Yu et al., 2008). In most tissues, TSPs are expressed at a low level compared to other The expression studies in human samples and in animal tissues non-structural ECM proteins, e.g., SPARC, tenascin C and fibronectin clearly suggest distinct functions and roles in physiological and patho- (Fig.
Load more

Recommended publications
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • Identification of Three Additional Genes Contiguous to the Glucocerebrosidase Locus on Chromosome 1Q21: Implications for Gaucher Disease Suzanne L
    Downloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press LETTER Identification of Three Additional Genes Contiguous to the Glucocerebrosidase Locus on Chromosome 1q21: Implications for Gaucher Disease Suzanne L. Winfield, Nahid Tayebi, Brian M. Martin, Edward I. Ginns, and Ellen Sidransky1 Clinical Neuroscience Branch, Intramural Research Program (IRP), National Institute of Mental Health, Bethesda, Maryland 20892 Gaucher disease results from the deficiency of the lysosomal enzyme glucocerebrosidase (EC 3.2.1.45). Although the functional gene for glucocerebrosidase (GBA) and its pseudogene (psGBA), located in close proximity on chromosome 1q21, have been studied extensively, the flanking sequence has not been well characterized. The recent identification of human metaxin (MTX) immediately downstream of psGBA prompted a closer analysis of the sequence of the entire region surrounding the GBA gene. We now report the genomic DNA sequence and organization of a 75-kb region around GBA, including the duplicated region containing GBA and MTX. The origin and endpoints of the duplication leading to the pseudogenes for GBA and MTX are now clearly established. We also have identified three new genes within the 32 kb of sequence upstream to GBA, all of which are transcribed in the same direction as GBA. Of these three genes, the gene most distal to GBA is a protein kinase (clk2). The second gene, propin1, has a 1.5-kb cDNA and shares homology to a rat secretory carrier membrane protein 37 (SCAMP37). Finally, cote1, a gene of unknown function lies most proximal to GBA. The possible contributions of these closely arrayed genes to the more atypical presentations of Gaucher disease is now under investigation.
    [Show full text]
  • Differences in Gene Expression Profiles and Carcinogenesis Pathways Involved in Cisplatin Resistance of Four Types of Cancer
    596 ONCOLOGY REPORTS 30: 596-614, 2013 Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer YONG YANG1,2, HUI LI1,2, SHENGCAI HOU1,2, BIN HU1,2, JIE LIU1,3 and JUN WANG1,3 1Beijing Key Laboratory of Respiratory and Pulmonary Circulation, Capital Medical University, Beijing 100069; 2Department of Thoracic Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020; 3Department of Physiology, Capital Medical University, Beijing 100069, P.R. China Received December 23, 2012; Accepted March 4, 2013 DOI: 10.3892/or.2013.2514 Abstract. Cisplatin-based chemotherapy is the standard Introduction therapy used for the treatment of several types of cancer. However, its efficacy is largely limited by the acquired drug Cisplatin is primarily effective through DNA damage and is resistance. To date, little is known about the RNA expression widely used for the treatment of several types of cancer, such changes in cisplatin-resistant cancers. Identification of the as testicular, lung and ovarian cancer. However, the ability RNAs related to cisplatin resistance may provide specific of cancer cells to become resistant to cisplatin remains a insight into cancer therapy. In the present study, expression significant impediment to successful chemotherapy. Although profiling of 7 cancer cell lines was performed using oligo- previous studies have identified numerous mechanisms in nucleotide microarray analysis data obtained from the GEO cisplatin resistance, it remains a major problem that severely database. Bioinformatic analyses such as the Gene Ontology limits the usefulness of this chemotherapeutic agent. Therefore, (GO) and KEGG pathway were used to identify genes and it is crucial to examine more elaborate mechanisms of cisplatin pathways specifically associated with cisplatin resistance.
    [Show full text]
  • A Systematic Genome-Wide Association Analysis for Inflammatory Bowel Diseases (IBD)
    A systematic genome-wide association analysis for inflammatory bowel diseases (IBD) Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Christian-Albrechts-Universität zu Kiel vorgelegt von Dipl.-Biol. ANDRE FRANKE Kiel, im September 2006 Referent: Prof. Dr. Dr. h.c. Thomas C.G. Bosch Koreferent: Prof. Dr. Stefan Schreiber Tag der mündlichen Prüfung: Zum Druck genehmigt: der Dekan “After great pain a formal feeling comes.” (Emily Dickinson) To my wife and family ii Table of contents Abbreviations, units, symbols, and acronyms . vi List of figures . xiii List of tables . .xv 1 Introduction . .1 1.1 Inflammatory bowel diseases, a complex disorder . 1 1.1.1 Pathogenesis and pathophysiology. .2 1.2 Genetics basis of inflammatory bowel diseases . 6 1.2.1 Genetic evidence from family and twin studies . .6 1.2.2 Single nucleotide polymorphisms (SNPs) . .7 1.2.3 Linkage studies . .8 1.2.4 Association studies . 10 1.2.5 Known susceptibility genes . 12 1.2.5.1 CARD15. .12 1.2.5.2 CARD4. .15 1.2.5.3 TNF-α . .15 1.2.5.4 5q31 haplotype . .16 1.2.5.5 DLG5 . .17 1.2.5.6 TNFSF15 . .18 1.2.5.7 HLA/MHC on chromosome 6 . .19 1.2.5.8 Other proposed IBD susceptibility genes . .20 1.2.6 Animal models. 21 1.3 Aims of this study . 23 2 Methods . .24 2.1 Laboratory information management system (LIMS) . 24 2.2 Recruitment. 25 2.3 Sample preparation. 27 2.3.1 DNA extraction from blood. 27 2.3.2 Plate design .
    [Show full text]
  • Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition
    Diabetes Care Volume 43, September 2020 2183 – Ele Ferrannini,1 Ashwin C. Murthy,2 Mechanisms of Sodium Glucose Yong-hoLee,3 ElzaMuscelli,1 SophieWeiss,4 Rachel M. Ostroff,4 Naveed Sattar,5 Cotransporter 2 Inhibition: Stephen A. Williams,4 and Peter Ganz6 Insights From Large-Scale Proteomics Diabetes Care 2020;43:2183–2189 | https://doi.org/10.2337/dc20-0456 OBJECTIVE To assess the effects of empagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, on broad biological systems through proteomics. RESEARCH DESIGN AND METHODS Aptamer-based proteomics was used to quantify 3,713 proteins in 144 paired plasma samples obtained from 72 participants across the spectrum of glucose tolerance before and after 4 weeks of empagliflozin 25 mg/day. The biology of the plasma proteins significantly changed by empagliflozin (at false discovery rate– corrected P < 0.05) was discerned through Ingenuity Pathway Analysis. RESULTS Empagliflozin significantly affected levels of 43 proteins, 6 related to cardiomyocyte function(fattyacid–bindingprotein3and4[FABPA],neurotrophic receptortyrosine kinase, renin, thrombospondin 4, and leptin receptor), 5 to iron handling (ferritin heavy chain 1, transferrin receptor protein 1, neogenin, growth differentiation CARDIOVASCULAR AND METABOLIC RISK factor 2 [GDF2], and b2-microglobulin), and 1 to sphingosine/ceramide metabolism 1CNR Institute of Clinical Physiology, Pisa, Italy (neutral ceramidase), a known pathway of cardiovascular disease. Among the 2 fi Cardiovascular Division, Department of Medi- protein changes achieving the strongest statistical signi cance, insulin-like binding cine, Hospital of the University of Pennsylvania, factor protein-1 (IGFBP-1), transgelin-2, FABPA, GDF15, and sulphydryl oxidase Philadelphia, PA 2 precursor were increased, while ferritin, thrombospondin 3, and Rearranged 3Department of Medicine, Severance Hospital, during Transfection (RET) were decreased by empagliflozin administration.
    [Show full text]
  • Phylogenomic Analysis of Vertebrate Thrombospondins Reveals Fish
    BMC Evolutionary Biology BioMed Central Research article Open Access Phylogenomic analysis of vertebrate thrombospondins reveals fish-specific paralogues, ancestral gene relationships and a tetrapod innovation Patrick McKenzie†1, Seetharam C Chadalavada†1, Justin Bohrer†1 and Josephine C Adams*1,2 Address: 1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic Foundation, Cleveland, OH 44195, USA and 2Dept. of Cell Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA Email: Patrick McKenzie - [email protected]; Seetharam C Chadalavada - [email protected]; Justin Bohrer - [email protected]; Josephine C Adams* - [email protected] * Corresponding author †Equal contributors Published: 18 April 2006 Received: 13 January 2006 Accepted: 18 April 2006 BMC Evolutionary Biology2006, 6:33 doi:10.1186/1471-2148-6-33 This article is available from: http://www.biomedcentral.com/1471-2148/6/33 © 2006McKenzie et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Thrombospondins (TSPs) are evolutionarily-conserved, extracellular, calcium- binding glycoproteins with important roles in cell-extracellular matrix interactions, angiogenesis, synaptogenesis and connective tissue organisation. Five TSPs, designated TSP-1 through TSP-5, are encoded in the human genome. All but one have known roles in acquired or inherited human diseases. To further understand the roles of TSPs in human physiology and pathology, it would be advantageous to extend the repertoire of relevant vertebrate models.
    [Show full text]
  • VPA Alleviates Neurological Deficits and Restores Gene Expression in a Mouse Model of Rett Syndrome
    VPA Alleviates Neurological Deficits and Restores Gene Expression in a Mouse Model of Rett Syndrome Weixiang Guo1.¤, Keita Tsujimura2., Maky Otsuka I.3, Koichiro Irie2, Katsuhide Igarashi3*, Kinichi Nakashima2*, Xinyu Zhao1* 1 Department of Neuroscience and Waisman Center, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America, 2 Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 3 Life Science Tokyo Advanced Research center (L-StaR), Hoshi University School of Pharmacy and Pharmaceutical Science, Tokyo, Japan Abstract Rett syndrome (RTT) is a devastating neurodevelopmental disorder that occurs once in every 10,000–15,000 live female births. Despite intensive research, no effective cure is yet available. Valproic acid (VPA) has been used widely to treat mood disorder, epilepsy, and a growing number of other disorders. In limited clinical studies, VPA has also been used to control seizure in RTT patients with promising albeit somewhat unclear efficacy. In this study we tested the effect of VPA on the neurological symptoms of RTT and discovered that short-term VPA treatment during the symptomatic period could reduce neurological symptoms in RTT mice. We found that VPA restores the expression of a subset of genes in RTT mouse brains, and these genes clustered in neurological disease and developmental disorder networks. Our data suggest that VPA could be used as a drug to alleviate RTT symptoms. Citation: Guo W, Tsujimura K, Otsuka I. M, Irie K, Igarashi K, et al. (2014) VPA Alleviates Neurological Deficits and Restores Gene Expression in a Mouse Model of Rett Syndrome.
    [Show full text]
  • Data-Driven and Knowledge-Driven Computational Models of Angiogenesis in Application to Peripheral Arterial Disease
    DATA-DRIVEN AND KNOWLEDGE-DRIVEN COMPUTATIONAL MODELS OF ANGIOGENESIS IN APPLICATION TO PERIPHERAL ARTERIAL DISEASE by Liang-Hui Chu A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland March, 2015 © 2015 Liang-Hui Chu All Rights Reserved Abstract Angiogenesis, the formation of new blood vessels from pre-existing vessels, is involved in both physiological conditions (e.g. development, wound healing and exercise) and diseases (e.g. cancer, age-related macular degeneration, and ischemic diseases such as coronary artery disease and peripheral arterial disease). Peripheral arterial disease (PAD) affects approximately 8 to 12 million people in United States, especially those over the age of 50 and its prevalence is now comparable to that of coronary artery disease. To date, all clinical trials that includes stimulation of VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor) have failed. There is an unmet need to find novel genes and drug targets and predict potential therapeutics in PAD. We use the data-driven bioinformatic approach to identify angiogenesis-associated genes and predict new targets and repositioned drugs in PAD. We also formulate a mechanistic three- compartment model that includes the anti-angiogenic isoform VEGF165b. The thesis can serve as a framework for computational and experimental validations of novel drug targets and drugs in PAD. ii Acknowledgements I appreciate my advisor Dr. Aleksander S. Popel to guide my PhD studies for the five years at Johns Hopkins University. I also appreciate several professors on my thesis committee, Dr. Joel S. Bader, Dr.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.655,397 B2 Khan Et Al
    USOO7655397B2 (12) United States Patent (10) Patent No.: US 7.655,397 B2 Khan et al. (45) Date of Patent: Feb. 2, 2010 (54) SELECTIONS OF GENES AND METHODS OF Li et al. Human Pathology. 2008. 39: 1792-1801.* USING THE SAME FOR DAGNOSIS AND Khan, J. et al. “Classification and diagnostic prediction of cancers FORTARGETING THE THERAPY OF using gene expression profiling and artificial neural networks'. SELECT CANCERS Nature Medicine, vol. 7, No. 6., pp. 673-679 (Jun. 2001). Peterson, C. et al., “JETNET 3.0—A versatile artificial neural net work package'. Computer Physics Communications, vol. 81, pp. (75) Inventors: Javed Khan, Derwood, MD (US); 185-220 (1994). Markus Ringnér, Lund (SE); Carsten Tusher, V. et al., “Significance analysis of microarrays applied to the Peterson, Lund (SE); Paul Meltzer, ionizing radiation response”., PNAS, vol. 98, No. 9, pp. 5116-5121 Rockville, MD (US) (Apr. 24, 2001). Van Gelder, R. et al., “Amplified RNA synthesized from limited (73) Assignee: The United States of America as quantities of heterogeneous cDNA'. Proc. Natl. Acad. Sci. USA, vol. represented by the Department of 87, No. 5, pp. 1663-1667 (Mar. 1990). Health and Human Services, Golub, T. etal. “Molecular Classification of Cancer, Class Discovery Washington, DC (US) and Class Prediction by Gene Expression Monitoring”, Science, 286:531-537 (1999). Gruvberger, S. et al., “Estrogen Receptor Status in Breast Cancer is (*) Notice: Subject to any disclaimer, the term of this Associated with Remarkably Distinct Gene Expression Patterns'. patent is extended or adjusted under 35 Cancer Research, 61:5979-5984 (2001). U.S.C.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.491,897 B2
    US0084.91897B2 (12) UnitedO States Patent (10) Patent No.: US 8.491,897 B2 Eroglu et al. (45) Date of Patent: Jul. 23, 2013 (54) TREATMENT OF NEUROPATHIC PAIN WO WO-0044895 A1 8, 2000 USING ANT-THROMBOSPONDIN W. W35A 38: ANTIBODES OTHER PUBLICATIONS (75) Inventors: Cagla Eroglu, Durham, NC (US); Ben A. Barres, Palo Alto, CA (US) Agah, A. et al. (2004). “Thrombospondin 2 Levels are Increased in s s Aged Mice: Consequences for Cutaneous Wound Healing and (73) Assignee: The Board of Trustees of the Leland Angiogenesis.” Matrix. Biol. 22:539-547. Stanford Junior University, Palo Alto, Alberts, B. et a al. (2002). Molecular Biology of the Cell, Fourth CA (US) Edition, Garland Science, New York, New York, p. 129. Apella, E. et al. (Apr. 1988). "Structure and Function of Epidermal (*) Notice: Subject to any disclaimer, the term of this Growth Factor-Like Regions in Proteins.” FEBS Lett. 231(1):1-4. patent is extended or adjusted under 35 Arber, S. etal. (Nov. 15, 2005). “Thrombospondin-4 an Extracellular U.S.C. 154(b) by 0 days Matrix Protein Expressed in the Developing and Adult Nervous Sys M YW- y yS. tem Promotes Neurite Outgrowth.” J. Cell Biol. 131(4): 1083-1094. (21) Appl. No.: 12/905,930 Arikkath, J. et al. (2003). “Auxiliary Subunits: Essential ppl. No.: 9 Componenets of the Voltage-Gated Calcium Complex.” Curr. Opin. 22) Filed: Oct. 15, 2010 Neurobiol. 13:298-307. (22) 1. 9 Ashkenazi, A. et al. (1995). “Immunoadhesins: An Alternative to (65) Prior Publication Data Human Monoclonal Antibodies.” Methods 8:104-115.
    [Show full text]
  • Blood Aging Is Correlated with Facial Aging
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260032; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Comparing the genetic and environmental architecture of blood count, blood biochemistry and urine biochemistry biological ages with machine learning Alan Le Goallec1,2+, Samuel Diai1+, Théo Vincent1, Chirag J. Patel1* 1Department of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA 2Department of Systems, Synthetic and Quantitative Biology, Harvard University, Cambridge, MA, 02118, USA +Co-first authors *Corresponding author Contact information: Chirag J Patel [email protected] Abstract While a large number of biological age predictors have been built from blood samples, a blood count-based biological age predictor is lacking, and the genetic and environmental factors associated with blood-measured accelerated aging remain elusive. In the following, we leveraged 31 blood count biomarkers measured from 489,079 blood samples, 28 blood biochemistry biomarkers measured from 245,147 blood samples, and four urine biochemistry biomarkers measured from 158,381 samples to build three distinct biological age predictors by training machine learning models to predict age. Blood biochemistry significantly outperformed blood count and urine biochemistry in terms of age prediction (RMSE: 5.92+-0.02 vs. 7.60+-0.02 years and 7.72+-0.04 years). We performed genome wide association studies [GWASs], and found accelerated blood biochemistry, blood count and urine biochemistry aging to be respectively 26.2+-0.3%, 18.1+-0.2% and 10.5±0.5% GWAS-heritable.
    [Show full text]
  • Lineage-Specific Programming Target Genes Defines Potential for Th1
    Downloaded from http://www.jimmunol.org/ by guest on October 1, 2021 is online at: average * The Journal of Immunology published online 26 August 2009 from submission to initial decision 4 weeks from acceptance to publication J Immunol http://www.jimmunol.org/content/early/2009/08/26/jimmuno l.0901411 Temporal Induction Pattern of STAT4 Target Genes Defines Potential for Th1 Lineage-Specific Programming Seth R. Good, Vivian T. Thieu, Anubhav N. Mathur, Qing Yu, Gretta L. Stritesky, Norman Yeh, John T. O'Malley, Narayanan B. Perumal and Mark H. Kaplan Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2009/08/26/jimmunol.090141 1.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* • Why • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of October 1, 2021. Published August 26, 2009, doi:10.4049/jimmunol.0901411 The Journal of Immunology Temporal Induction Pattern of STAT4 Target Genes Defines Potential for Th1 Lineage-Specific Programming1 Seth R. Good,2* Vivian T. Thieu,2† Anubhav N. Mathur,† Qing Yu,† Gretta L.
    [Show full text]